Terns Pharmaceuticals Inc... (TERN)
3.51
-0.18 (-4.88%)
At close: Mar 03, 2025, 12:26 PM
Terns Pharmaceuticals Balance Sheet Statement
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
Cash & Equivalents | 79.93M | 143.24M | 47.7M | 74.85M | 12.33M | 82.52M |
Short-Term Investments | 183.51M | 139.88M | 118.28M | n/a | 7.32M | 4.36M |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 56K | 37K | 94K | 246K | 719K | 335K |
Receivables | n/a | n/a | n/a | 12.72M | n/a | n/a |
Inventory | n/a | n/a | n/a | 2.97M | n/a | n/a |
Other Current Assets | 3.99M | 2.07M | 1.9M | 3.3M | 2.57M | 1.59M |
Total Current Assets | 267.43M | 285.19M | 166.93M | 90.87M | 22.22M | 88.48M |
Property-Plant & Equipment | 1.03M | 1.8M | 1.05M | 1.18M | 961K | 261K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 1.08M | 1.84M | 1.14M | 1.42M | 1.68M | 596K |
Total Assets | 268.52M | 287.03M | 168.07M | 92.29M | 23.9M | 89.07M |
Account Payables | 2.52M | 1.65M | 2.13M | 935K | 1.64M | 914K |
Deferred Revenue | n/a | n/a | n/a | 836K | n/a | n/a |
Short-Term Debt | 603K | 1.32M | n/a | 12.88M | n/a | n/a |
Other Current Liabilities | 7.62M | 4.43M | 3.91M | 7.51M | 3.31M | 1.46M |
Total Current Liabilities | 11.94M | 8.47M | 6.82M | 22.82M | 4.95M | 2.38M |
Long-Term Debt | n/a | 544K | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 1.21M | 1.07M | 947K | 877K | 14.4M | 14.32M |
Total Long-Term Liabilities | 1.21M | 1.61M | 947K | 877K | 14.75M | 14.47M |
Total Liabilities | 13.15M | 10.08M | 7.77M | 23.7M | 19.7M | 16.84M |
Total Debt | 603K | 1.21M | n/a | 12.88M | n/a | n/a |
Common Stock | 6K | 5K | 3K | n/a | n/a | n/a |
Retained Earnings | -332.63M | -242.42M | -182.07M | -131.91M | -91.86M | -23.25M |
Comprehensive Income | -19K | -822K | -338K | -124K | -106K | 59K |
Shareholders Equity | 255.37M | 276.94M | 160.3M | 68.59M | 4.21M | 72.23M |
Total Investments | 183.51M | 139.88M | 118.28M | n/a | 7.32M | 4.36M |